Keywords: blow, amgen, fda, panel, calls, restrictions, anemia
Blow for Amgen and J&J as FDA panel calls for restrictions on anemia drugs
Article | 21 May 2007
Following the US Food and Drug Administration's recent public health advisory calling for strengthened product labeling for erythropoeisis-stimulating agents (ESAs), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
